<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043792</url>
  </required_header>
  <id_info>
    <org_study_id>TT00920US03</org_study_id>
    <nct_id>NCT05043792</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of TT-00920 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransThera Sciences (Nanjing), Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransThera Sciences (Nanjing), Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multiple ascending dose escalation&#xD;
      study of TT-00920 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multiple ascending dose escalation&#xD;
      study of TT-00920 in healthy subjects. Each dosing cohort will be comprised of 10 randomized&#xD;
      subjects dosed three times daily for 13 days and one time for 1 day. The study will consist&#xD;
      of a Screening Period, an In-house Period and a Follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of TEAEs and clinically relevant changes in safety parameters,e.g. clinical laboratory tests, 12-lead ECG, ophthalmological examination [Safety and tolerability]</measure>
    <time_frame>14 days</time_frame>
    <description>TEAE: Treatment emergent adverse events&#xD;
Safety parameters: physical examinations, vital signs, clinical laboratory tests , 12-lead ECG in triplicate, cardiac Holter monitoring, visual tests and ophthalmological examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration versus time curve at steady state (AUC0-t, ss and AUC0-τ, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration at steady state (Cmax, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time corresponding to occurrence of Cmax,ss at steady state (Tmax, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration at steady state (Cmin, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cav)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vz/F, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance at steady state (CL/F, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life at steady state (T1/2, ss)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolite characterization in plasma and estimation</measure>
    <time_frame>14 days</time_frame>
    <description>observed drug-related material in plasma to determine the presence of any metabolite &gt;10%</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Biomarkers From Baseline to Day 14: cGMP (Pmol/mL)</measure>
    <time_frame>14 days</time_frame>
    <description>cGMP: cyclic guanosine monophosphate</description>
  </other_outcome>
  <other_outcome>
    <measure>Utilization of PGx results</measure>
    <time_frame>14 days</time_frame>
    <description>A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose 1 (Low dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 (Middle dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 (High dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TT-00920 Placebo, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TT-00920</intervention_name>
    <description>TT-00920 Tablets</description>
    <arm_group_label>Dose 1 (Low dose)</arm_group_label>
    <arm_group_label>Dose 2 (Middle dose)</arm_group_label>
    <arm_group_label>Dose 3 (High dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TT-00920 Placebo</intervention_name>
    <description>TT-00920 Placebo Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained&#xD;
&#xD;
          -  Age ≥ 18.0 years and ≤ 55.0 years, male or female&#xD;
&#xD;
          -  BMI between 18.0 and 30.0 kg/m2, inclusive, and weighs at least 50.0 kg&#xD;
&#xD;
          -  No clinically significant findings in medical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to lactose&#xD;
&#xD;
          -  Vaccination with any live vaccine, or vaccination employing an mRNA platform within 28&#xD;
             days and/or vaccination with any inactivated vaccine within 7 days of study drug&#xD;
             administration&#xD;
&#xD;
          -  Impaired cardiac function including clinically significant arrhythmias or clinically&#xD;
             significant abnormality&#xD;
&#xD;
          -  HbA1c &gt; 5.7 % at Screening&#xD;
&#xD;
          -  Subject with a history of severe visual diseases; or visual changes&#xD;
&#xD;
          -  Subject is unable to complete this study for other reasons or the Investigator&#xD;
             believes that he or she should be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Yu</last_name>
    <phone>17366389262</phone>
    <email>yuyan@transtherabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Chen</last_name>
    <phone>19825055302</phone>
    <email>chen_ying@transtherabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pharmaron CPC, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Milzman</last_name>
      <phone>240-705-3926</phone>
      <email>jacqueline.milzman@pharmaron-us.com</email>
    </contact>
    <investigator>
      <last_name>Paolo DePetrillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

